news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
The BIO International Convention brings together the leaders in the biotechnology and pharmaceutical industries. A “can’t miss” Event!
We look forward to sharing updates on DAV132 and meeting with both current and potential partners! Do not hesitate to reach out to our Business Development team at bd@davolterra.com.
Website Event link here
